Kolkisin Tiofarma

Colchicine, the active ingredient in Kolkisin Tiofarma, is an alkaloid (microtubule inhibitor) presented as an oral formulation for oral use. It treats acute gout flares and helps prevent attacks in adults with gout or familial Mediterranean fever.

GNH USA supplies Kolkisin Tiofarma as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Colchicine is used to manage conditions involving inflammatory crystal deposition and hereditary autoinflammatory episodes. - Acute gout flares: rapidly reduces pain, swelling and inflammation during an attack. - Prophylaxis of gout attacks: lowers the frequency of recurrent gout episodes when taken regularly. - Familial Mediterranean fever: prevents febrile attacks and associated serosal inflammation.

Colchicine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal pain, or cramping. - Diarrhea: frequent loose stools. - Vomiting: occasional episodes of emesis. - Loss of appetite: reduced desire to eat.

Serious or Rare Side Effects: - Bone marrow suppression: leading to neutropenia or aplastic anemia. - Severe muscle toxicity: rhabdomyolysis or myopathy. - Hepatotoxicity: elevated liver enzymes or liver injury. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Multi‑organ failure: in cases of extreme overdose.

When prescribing colchicine, clinicians should consider several safety measures. - Dose adjustment in renal impairment: reduce dose or increase monitoring frequency. - Avoid in severe hepatic dysfunction: contraindicated due to impaired metabolism. - Monitor blood counts regularly: watch for neutropenia or anemia. - Use caution with concomitant CYP3A4 inhibitors: may increase colchicine exposure. - Store at room temperature: keep in the original container, protect from moisture and light.

Colchicine interacts with several drug classes that can alter its safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): risk of toxic accumulation. - P‑glycoprotein inhibitors (e.g., cyclosporine, verapamil): increase systemic exposure. - High‑dose statins (e.g., simvastatin): heightened risk of myopathy.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., diltiazem, erythromycin): may require dose adjustment. - Diuretics (e.g., furosemide): can affect renal clearance of colchicine. - Macrolide antibiotics (e.g., azithromycin): monitor for signs of toxicity.